VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer

Journal of Thoracic Disease

Volumn 5, Issue 5, 2013, Pages 578-584

  Zhi, Xiuyi ^a   Gao, Wen ^b   Han, Baohui ^c   Yang, Yue ^d   Li, Hui ^a   Liu, Deruo ^e   Wang, Changli ^f   Min, Gong ^a   Long, Hao ^g   Rigas, James R ^h   Carey, Mark ^h   Jahan, Thierry ⁱ   Sammann, Amanda ⁱ   Reza, Joseph ⁱ   Wang, Daoyuan ^j   Mann, Michael J ⁱ   Jablons, David M ⁱ   He, Jianxing ^j  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^e Beijing Sino Japan Hospital   (China)

^f TIANJIN MEDICAL UNIVERSITY   (China)

^g SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j GUANGZHOU MEDICAL UNIVERSITY   (China)

more..

Author keywords

Adjuvant chemotherapy; Carboplatin; Docetaxel; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL;

ADJUVANT THERAPY; ADULT; AGED; ALLERGIC REACTION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHINA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; LOBECTOMY; LUNG NON SMALL CELL CANCER; MALE; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PATIENT ASSESSMENT; PELVIC INFLAMMATORY DISEASE; PLEURA EFFUSION; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; THORACOTOMY; THROMBOCYTOPENIA; VATS LOBECTOMY; VIDEO ASSISTED THORACOSCOPIC SURGERY; VOMITING;

EID: 84888375961     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.02.05     Document Type: Article

References (21)

1. Zhao Y, Kosorok MR, Zeng D. Reinforcement learning design for cancer clinical trials. Stat Med 2009;28:3294-315.
2. Shao W, Wang D, He J. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis 2010;2:89-99.
3. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
4. Voon PJ, Chul Cho B, Yeo WL, et al. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J Thorac Dis 2010;2:144-53.
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
6. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
7. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
8. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
9. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
10. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24.
11. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:5116-23.
12. Stinchcombe TE, Harper HD, Hensing TA, et al. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol 2008;3:145-51.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
14. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
15. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
16. Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 2009;6:194-200.
17. Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14:449-54.
18. Petersen RP, Pham D, Burfeind WR, et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg 2007;83:1245-9; discussion 1250.
19. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment GroupStudy Groups. J Clin Oncol 2008;26:5043-51.
20. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003;95:1453-61.
21. He J, Shao W, Li S, et al. Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC. J Thorac Dis 2009;1:55-62.